Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 1;110(3):791-794.
doi: 10.3324/haematol.2024.286332.

Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience

Marika Porrazzo  1 , Tiziana Moscato  2 , Giuseppe Sapienza  3 , Fabrizio Accardi  1 , Caterina Patti  1 , Clotilde Cangialosi  1 , Carmelo Costanza  1 , Roberto Bono  3 , Stefania Tringali  3 , Cristina Rotolo  3 , Emilia Gigliotta  4 , Andrea Rizzuto  4 , Manuela Giuseppa Ingrascè  4 , Giulia Butera  4 , Laura Di Noto  5 , Alessandra Santoro  6 , Anna Marfia  6 , Cirino Botta  4 , Sergio Siragusa  4 , Massimo Martino  2 , Luca Castagna  7
Affiliations

Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience

Marika Porrazzo et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram of mobilization of peripheral blood stem cells in patients with newly diagnosed multiple myeloma. TE-NDMM: transplant-eligible newly diagnosed multiple myeloma; G-CSF: granulocyte colony-stimulating factor; CT: chemotherapy.
See this image and copyright information in PMC

References

    1. Dimopoulos MA, Moreau P, Terpos E, et al. . Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309-322. - PubMed
    1. Giralt S, Costa L, Schriber J, et al. . Optimizing autologous stem cell mobilization strategies to improve patients outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295-308. - PubMed
    1. Di Persio JF, Stadtmauer EA, Nademanee A, et al. . Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726. - PubMed
    1. Venglar O, Kapustova V, Sithara AA, et al. . Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy. Br J Haematol. 2024;204(4):1439-1449. - PubMed
    1. Moreau P, Attal M, Hulin C, et al. . Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29-38. - PubMed

LinkOut - more resources